Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc. (TVTX), sold 21,977 shares at $41.07 ($903K) on 2026-04-14, disclosed to the SEC on 2026-04-16.
Scheduled sale ($903k) by SVP, CHIEF ACCOUNTING OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |
| TVTX | SELL | 2025-11-06 | $2.4M | — | Filing → |